high mobility group nucleosome binding domain 1 pseudogene 37Genealiases: []
Q-omics provides the consensus-scored HMGN1P37 profile across patient tissues and cancer cell-line models. HMGN1P37 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HMGN1P37 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, HMGN1P37 RNA expression shows 17,877 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where HMGN1P37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN1P37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN1P37 survival associations across molecular data types. HMGN1P37 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN1P37 RNA expression–survival associations across cancer types. High HMGN1P37 expression shows unfavorable associations in ACC, UVM, MESO, LGG, SARC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HMGN1P37 RNA expression.
This table summarizes HMGN1P37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN1P37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN1P37 shows lower tumor expression in KICH and COAD and higher tumor expression in BLCA, HNSC, LUAD and BRCA. The BLCA box plot shows higher HMGN1P37 RNA expression in tumor versus normal tissue (log2 FC = +1.102, t-test p < 0.001).
This table shows molecular features associated with HMGN1P37 in patient tissues and cancer cell lines. In patient samples, HMGN1P37 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
